

Financial news for PPHMP dated on 2017-11-28: Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement; Peregrine Board Reconstituted with Four New Independent Directors

Financial news for PPHMP dated on 2016-10-24: Peregrine Pharmaceuticals Preclinical Research Shows PS-Targeting Antibody With Anti PD-L1 Therapy Led To Greater Anti-Tumor Activity Than Single Agent Treatment Or Dual Combinations With Chemotherapy

Financial news for PPHMP dated on 2016-09-27: Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer

Financial news for PPHMP dated on 2016-07-14: Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center, Offers Value Creation And Early Partnering Opportunities

Financial news for PPHMP dated on 2016-01-11: Peregrine Pharmaceuticals, AstraZeneca Evaluating Bavituximab Plus Durvalumab To Expand Lung Cancer Program Q1 2016

Financial news for PPHMP dated on 2016-01-06: Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab

Financial news for PPHMP dated on 2015-11-09: New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma

Financial news for PPHMP dated on 2015-10-15: AstraZeneca, Peregrine Pharmaceuticals Increase Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial

Financial news for PPHMP dated on 2015-09-08: New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression

Financial news for PPHMP dated on 2015-08-26: Peregrine Pharmaceuticals Presents Data at Annual Immunotherapy and Vaccine Summit (ImVacS) Supporting Ability of Bavituximab to Mediate Anti-Tumor T Cell Responses Across Multiple Tumor Types

Financial news for PPHMP dated on 2015-06-25: Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab

Financial news for PPHMP dated on 2015-06-01: Data Presentations at ASCO Demonstrate the Ability of Peregrine Pharmaceuticals' Bavituximab to Activate Tumor Targeting Immune Cells in PD-L1 Negative NSCLC Tumors

Financial news for PPHMP dated on 2015-06-01: Peregrine Pharma Announces Presentations at ASCO Showed Ability of Bavituximab to Activate Tumor Target Immune Cells in PD-L1 Negative NSCLC Tumors

Financial news for PPHMP dated on 2015-06-01: Peregrine Pharmaceuticals Gives Update on Expansion of Bavituximab Clinical Program

Financial news for PPHMP dated on 2015-05-29: Peregrine Pharmaceuticals Enters Into Research Partnership to Investigate Novel PS-Targeting Immunotherapy Combinations

Financial news for PPHMP dated on 2015-04-21: Preclinical Data Shown at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals' Phosphatidylserine -Targeting Antibodies With Immune Checkpoint Inhibitors in Models of Melanoma and Breast Cancer

Financial news for PPHMP dated on 2015-04-14: Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting

Financial news for PPHMP dated on 2015-03-31: Peregrine Pharma Phase 2 Design Trial Underway

Financial news for PPHMP dated on 2015-03-31: Peregrine Pharma Announces Positive Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine

Financial news for PPHMP dated on 2014-12-10: Avid Bioservices Announces Expansion Of cGMP Manufacturing Capacity